DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacokinetic Evaluation of Moxifloxacin Administered Intravenously and Orally in Healthy Volunteers Who Have Had a Gastric Bypass

Information source: University Ghent
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Gastric Bypass; Body Weight

Intervention: moxifloxacin per IV (Drug); moxifloxacin per os (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: University Ghent

Official(s) and/or principal investigator(s):
Jan Van Bocxlaer, PhD, Principal Investigator, Affiliation: University Ghent

Summary

Roux-and-Y gastric bypass is one of the most common forms of bariatric surgery; due to a reduction in size of the stomach and intestine, the available surface area for the absorption of oral drugs is strongly decreased. This may lead to a reduced bioavailability resulting in a reduced efficacy of the drug. However, in literature there is no information available about the impact of bariatric surgery on the pharmacokinetics of moxifloxacin. This protocol evaluates the moxifloxacin plasma levels, the variability between subjects and the absolute bioavailability, after oral administration of 400 mg moxifloxacin in healthy volunteers who have had a gastric bypass at least 6 months ago and who now have a stable body weight.

Clinical Details

Official title: Pharmacokinetic Evaluation of Moxifloxacin Administered Intravenously and Orally in Healthy Volunteers Who Have Had a Gastric Bypass.

Study design: Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: To evaluate the pharmacokinetics of 400 mg moxifloxacin per IV compared to 400 mg moxifloxacin per os in patients who had a gastric bypass

Eligibility

Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy volunteers who have had a gastric bypass at least 6 months ago and whose body

weight has not changed more than 5% during the last 3 months

- Age between 18 and 60 years old

- Able to give informed consent

Exclusion Criteria:

- Other forms of bariatric surgery (Scopinaro and Mason/Sleeve) before gastric bypass

surgery

- Hypersensitivity to moxifloxacin, other quinolones or to any of the excipients

- Pregnancy and lactation

- Creatinine clearance < 80 ml/min

- Transaminases > 2x the upper limit of normal (AST/ALT)

- Impaired liver function (Child Pugh C)

- Fasting glycaemia > 125mg/dl

- Epilepsy

- Patients with a history of tendon disease/disorder (especially Achilles tendon

rupture) related to quinolone treatment

- Patients with the following heart disorders:

- Electrolyte disturbance, particularly an uncorrected hypokalaemia

- Clinically relevant bradycardia

- Clinically relevant heart failure with reduced left-ventricular ejection

fraction

- Previous history of symptomatic arrhythmias

- Congenital or documented acquired QT prolongation or concurrently use of drugs that

prolong the QT interval:

- anti-arrhythmics (Classes IA and III)

- neuroleptics

- tricyclic antidepressants

- antimicrobials (e. g. sparfloxacin, intravenous erythromycin, pentamidine,

antimalarials particularly halofantrine)

- some antihistamines (e. g. terfenadine, astemizole, mizolastine)

- cisapride, intravenous vincamine, bepridil and diphemanil

- No normal thyroid function

- All clinically significant disorders that can interfere with the study

Locations and Contacts

University Hospital Ghent, Ghent, Belgium
Additional Information

Starting date: March 2010
Last updated: April 15, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017